• Skip to main content
  • Skip to footer
Eco Friendly CBD OIL

Eco Friendly CBD OIL

The Best Eco Friendly CBD Oil

  • Home
  • CBD Health
  • Cannabis News
  • Contact

CBD OIL

Mexico’s Health Ministry Publishes Medical Cannabis Rules

January 13, 2021 by CBD OIL

Cannabis genetics are the cornerstone of Green Dot Labs’ Boulder, Colo.-based concentrates operation, and according to co-founder Dave Malone, the craft beer industry provided the inspiration he needed to give the company’s unique cultivars their own identities.

Malone says the craft brewing industry started out as a select few companies with lines of beers that were almost indistinguishable among consumers, but as soon as brands began investing in marketing, consumers started gravitating toward specific brands.

The cannabis industry, he says, has a lot to learn from this approach.

“That’s what we’re aiming to do with our genetics, is give them their own identity,” Malone says. “People may prefer different brands for whatever reason, but they still look at our Cherry Fluff strain, for instance, which is [branded as] a beautiful cherry on a big pile of whipped cream, and [the marketing is] very captivating and seductive. People identify with that.”

Photo courtesy of Green Dot Labs

Green Dot Labs’ Peach Brain Freeze cultivar

Dan Banks, director of cultivation strategy for Denver- based Lightshade, echoes this sentiment, adding that marketing is beginning to play a large role in the cannabis genetics space, with name-brand recognition starting to emerge among consumers.

“You have a couple different demographics,” Banks says. “You have people who are used to getting certain things from dispensaries, [and] they want to see those things maintained. Then you have people who are interested in anything new and checking that out, and if it’s new, then they’re like, ‘I want more of that’ or ‘I want more from that lineage.’”

Founded in 2011, Lightshade is one of the largest Colorado-owned, vertically integrated cannabis operators in the state. The company operates a greenhouse operation in Denver, as well as four indoor grow facilities.

When Banks joined Lightshade in late 2019, the company was cultivating roughly a dozen varieties across its five facilities, but it has since grown its genetics library to nearly 70 cultivars, with roughly 30 in regular production.

“Over the last year and some change, we’ve grown the library of genetics in the company and then implemented what we call a phenotyping program,” Banks says. “Basically, that’s a systematic way of introducing new varieties into production and gathering information about their performance, both on the horticultural side and also on the quality [and] potency side, as well.”

Lightshade acquired vertically integrated cannabis operator Sacred Seed last summer, which provided the company with a large bank of new genetics. Heading into 2021, Lightshade will establish an in-house breeding program to produce unique and proprietary varieties.

“[We’re] really trying to get some unique variety, … while also trying to cater to consumers that are looking for specific name-brand strains, as well,” Banks says, adding, “A lot of the things that people are excited about right now, there’s a lot of marketing behind that. Sometimes that marketing has a lot of substance backing it up, and other times it’s just a lot of hype.”

Photo courtesy of Lightshade

Lightshade plans to establish an in-house breeding program this year to produce unique and proprietary cannabis varieties.

Along those same lines, Malone says that companies can invest in robust marketing for a mediocre product, but that product still won’t do as well as better-quality offerings—product quality and marketing must go hand in hand.

“You can put all of the branding in the world on a jar of undifferentiated product and it won’t do well, but if you have integrity from the core, which is your genetics, it really extrapolates the value downstream when you do add these marketing layers to the product,” he says.

Green Dot Labs is entering its seventh year and maintains an in-house breeding program to create genetics specifically for its extracts.

“A lot of cannabis companies are curating genetics through a vast network that are available worldwide, whereas we’ve taken that into our own hands and steered the ship toward the goals that we set out, [so we’re] not necessarily … at the mercy of the market to provide content for the brand,” Malone says.

As it breeds new strains, Green Dot Labs brands them, which Malone says has become especially important in recent years as consumers have started to expect more from cannabis extracts.

“The consumer wants to know more,” he says. “They want to know the heritage, the lineage, where the strain came from, [and] what kind of flavors and experience they can expect when they open the package.”

Green Dot Labs has roughly 20 branded strains in its genetics library, and Malone says the branded cultivars outsell the company’s non-branded offerings, 3-to-1.

“There is so much content out there for the average consumer,” he says. “It’s overwhelming to find what strains work best for you. Everything in the current market, specifically here in Colorado, is extremely generic. A lot of companies haven’t taken this extra measure to differentiate their genetic portfolios.”

It’s a cultivator’s responsibility to tell the consumer why his or her product is better than others through branding, Malone says. The main points of brand differentiation, he adds, will be proprietary genetics that offer unique flavors and experiences, as well as the quality and efficiency with which these cultivars are produced.

Creating a Differentiated Experience

When Green Dot Labs launched its breeding program, Malone says it took a qualitative approach. The company pursued genetics that mirrored nearly every type of fruit, from a banana to an apple, and also started breeding what he calls “gassy” varieties. Since not all genetics are created equal when it comes to performing well in the extraction process, data collected during extraction helped the Green Dot Labs team further refine its genetics offerings. Specifically, the company looked at extract yields, and pursued cultivars with differentiated flavors that offered as much resin as possible.

Green Dot Labs recently closed on a new facility in Colorado that will allow the company to expand and increase its R&D capacity as it heads into the new year.

“We’re going to be delivering new strains and new flavors that have never even been imagined by the most sophisticated cannabis connoisseur,” Malone says. “That’s the goal now.”

Another one of the company’s goals, he adds, is to find strains that perform well during solventless extraction.

Photo courtesy of Green Dot Labs

Green Dot Labs will expand its extracts line this year by improving the resin structure of its favorite plants while also creating new cultivars.

“You see a lot of connoisseurs wanting to enjoy the solventless extract, but the problem with this and why it’s so expensive is because your yields are highly unpredictable and heavily predicated on the quality of the plants you produce and the genetics,” Malone says, adding that Green Dot Labs currently has 10 cultivars in its genetics library that work well with solventless extraction.

As the company heads into 2021, it will expand its extracts line by improving the resin structure of its favorite plants while also creating new cultivars.

“We like to offer something for everyone,” Malone says. “Each consumer has a certain taste, and we don’t want to alienate anybody. We want to make it so anybody who likes cannabis can come to Green Dot Labs and this can be their one-stop shop.”

For Banks and the Lightshade team, 2021 will be focused on establishing the company’s breeding program, which will include sourcing more genetic material and identifying desirable plants to work with.

“What we’ll do is try to establish a bank of male plants that we can then use to start crossing with females, and the other thing that we’ll do is look at partnering with some of the companies that are offering genetic mapping in order to get a better understanding of the source genetics that we have,” Banks says. “You bring something in and it has a name, but is it what they’re saying it is? We don’t know, but we can look into that.”

The market continues to change rapidly as consumers gain a better understanding of terpene profiles and minor cannabinoids, adds Nick Drury, Lightshade’s director of cultivation operations, and Lightshade will lean into consumer education and marketing to address these topics.

“People are realizing that it’s not just about THC content,” Drury says. “It’s also about your overall terpene profile, and how those terpenes and cannabinoids are interacting to produce a high. As people start to increase their own education into certain things, I think what you’ll start to see in the market as a whole is a shift … in terms of what people are looking for, and a little bit more interest in specific profiles, [which will do] away with the indica/sativa/hybrid terminology. … That will open up the market to a lot of cultivars that may be low in overall THC, but they might be high in CBN and all these other cannabinoids and all the different terpene profiles. … I would say education and marketing are huge in the upcoming year.”

“I think branding is just going to become more important than ever,” Malone adds. “[With] the quality [and] the differentiation being so vast, how you present the product to the consumer is really where the rubber is going to hit the road once competition elevates to this level.”

Filed Under: Cannabis News

How Unique Cannabis Genetics Drive Brand Building

January 13, 2021 by CBD OIL

Cannabis genetics are the cornerstone of Green Dot Labs’ Boulder, Colo.-based concentrates operation, and according to co-founder Dave Malone, the craft beer industry provided the inspiration he needed to give the company’s unique cultivars their own identities.

Malone says the craft brewing industry started out as a select few companies with lines of beers that were almost indistinguishable among consumers, but as soon as brands began investing in marketing, consumers started gravitating toward specific brands.

The cannabis industry, he says, has a lot to learn from this approach.

“That’s what we’re aiming to do with our genetics, is give them their own identity,” Malone says. “People may prefer different brands for whatever reason, but they still look at our Cherry Fluff strain, for instance, which is [branded as] a beautiful cherry on a big pile of whipped cream, and [the marketing is] very captivating and seductive. People identify with that.”

Photo courtesy of Green Dot Labs

Green Dot Labs’ Peach Brain Freeze cultivar

Dan Banks, director of cultivation strategy for Denver- based Lightshade, echoes this sentiment, adding that marketing is beginning to play a large role in the cannabis genetics space, with name-brand recognition starting to emerge among consumers.

“You have a couple different demographics,” Banks says. “You have people who are used to getting certain things from dispensaries, [and] they want to see those things maintained. Then you have people who are interested in anything new and checking that out, and if it’s new, then they’re like, ‘I want more of that’ or ‘I want more from that lineage.’”

Founded in 2011, Lightshade is one of the largest Colorado-owned, vertically integrated cannabis operators in the state. The company operates a greenhouse operation in Denver, as well as four indoor grow facilities.

When Banks joined Lightshade in late 2019, the company was cultivating roughly a dozen varieties across its five facilities, but it has since grown its genetics library to nearly 70 cultivars, with roughly 30 in regular production.

“Over the last year and some change, we’ve grown the library of genetics in the company and then implemented what we call a phenotyping program,” Banks says. “Basically, that’s a systematic way of introducing new varieties into production and gathering information about their performance, both on the horticultural side and also on the quality [and] potency side, as well.”

Lightshade acquired vertically integrated cannabis operator Sacred Seed last summer, which provided the company with a large bank of new genetics. Heading into 2021, Lightshade will establish an in-house breeding program to produce unique and proprietary varieties.

“[We’re] really trying to get some unique variety, … while also trying to cater to consumers that are looking for specific name-brand strains, as well,” Banks says, adding, “A lot of the things that people are excited about right now, there’s a lot of marketing behind that. Sometimes that marketing has a lot of substance backing it up, and other times it’s just a lot of hype.”

Photo courtesy of Lightshade

Lightshade plans to establish an in-house breeding program this year to produce unique and proprietary cannabis varieties.

Along those same lines, Malone says that companies can invest in robust marketing for a mediocre product, but that product still won’t do as well as better-quality offerings—product quality and marketing must go hand in hand.

“You can put all of the branding in the world on a jar of undifferentiated product and it won’t do well, but if you have integrity from the core, which is your genetics, it really extrapolates the value downstream when you do add these marketing layers to the product,” he says.

Green Dot Labs is entering its seventh year and maintains an in-house breeding program to create genetics specifically for its extracts.

“A lot of cannabis companies are curating genetics through a vast network that are available worldwide, whereas we’ve taken that into our own hands and steered the ship toward the goals that we set out, [so we’re] not necessarily … at the mercy of the market to provide content for the brand,” Malone says.

As it breeds new strains, Green Dot Labs brands them, which Malone says has become especially important in recent years as consumers have started to expect more from cannabis extracts.

“The consumer wants to know more,” he says. “They want to know the heritage, the lineage, where the strain came from, [and] what kind of flavors and experience they can expect when they open the package.”

Green Dot Labs has roughly 20 branded strains in its genetics library, and Malone says the branded cultivars outsell the company’s non-branded offerings, 3-to-1.

“There is so much content out there for the average consumer,” he says. “It’s overwhelming to find what strains work best for you. Everything in the current market, specifically here in Colorado, is extremely generic. A lot of companies haven’t taken this extra measure to differentiate their genetic portfolios.”

It’s a cultivator’s responsibility to tell the consumer why his or her product is better than others through branding, Malone says. The main points of brand differentiation, he adds, will be proprietary genetics that offer unique flavors and experiences, as well as the quality and efficiency with which these cultivars are produced.

Creating a Differentiated Experience

When Green Dot Labs launched its breeding program, Malone says it took a qualitative approach. The company pursued genetics that mirrored nearly every type of fruit, from a banana to an apple, and also started breeding what he calls “gassy” varieties. Since not all genetics are created equal when it comes to performing well in the extraction process, data collected during extraction helped the Green Dot Labs team further refine its genetics offerings. Specifically, the company looked at extract yields, and pursued cultivars with differentiated flavors that offered as much resin as possible.

Green Dot Labs recently closed on a new facility in Colorado that will allow the company to expand and increase its R&D capacity as it heads into the new year.

“We’re going to be delivering new strains and new flavors that have never even been imagined by the most sophisticated cannabis connoisseur,” Malone says. “That’s the goal now.”

Another one of the company’s goals, he adds, is to find strains that perform well during solventless extraction.

Photo courtesy of Green Dot Labs

Green Dot Labs will expand its extracts line this year by improving the resin structure of its favorite plants while also creating new cultivars.

“You see a lot of connoisseurs wanting to enjoy the solventless extract, but the problem with this and why it’s so expensive is because your yields are highly unpredictable and heavily predicated on the quality of the plants you produce and the genetics,” Malone says, adding that Green Dot Labs currently has 10 cultivars in its genetics library that work well with solventless extraction.

As the company heads into 2021, it will expand its extracts line by improving the resin structure of its favorite plants while also creating new cultivars.

“We like to offer something for everyone,” Malone says. “Each consumer has a certain taste, and we don’t want to alienate anybody. We want to make it so anybody who likes cannabis can come to Green Dot Labs and this can be their one-stop shop.”

For Banks and the Lightshade team, 2021 will be focused on establishing the company’s breeding program, which will include sourcing more genetic material and identifying desirable plants to work with.

“What we’ll do is try to establish a bank of male plants that we can then use to start crossing with females, and the other thing that we’ll do is look at partnering with some of the companies that are offering genetic mapping in order to get a better understanding of the source genetics that we have,” Banks says. “You bring something in and it has a name, but is it what they’re saying it is? We don’t know, but we can look into that.”

The market continues to change rapidly as consumers gain a better understanding of terpene profiles and minor cannabinoids, adds Nick Drury, Lightshade’s director of cultivation operations, and Lightshade will lean into consumer education and marketing to address these topics.

“People are realizing that it’s not just about THC content,” Drury says. “It’s also about your overall terpene profile, and how those terpenes and cannabinoids are interacting to produce a high. As people start to increase their own education into certain things, I think what you’ll start to see in the market as a whole is a shift … in terms of what people are looking for, and a little bit more interest in specific profiles, [which will do] away with the indica/sativa/hybrid terminology. … That will open up the market to a lot of cultivars that may be low in overall THC, but they might be high in CBN and all these other cannabinoids and all the different terpene profiles. … I would say education and marketing are huge in the upcoming year.”

“I think branding is just going to become more important than ever,” Malone adds. “[With] the quality [and] the differentiation being so vast, how you present the product to the consumer is really where the rubber is going to hit the road once competition elevates to this level.”

Filed Under: Cannabis News

Advancements in Extraction & the Growth of the Concentrate Category

January 13, 2021 by CBD OIL

Due to quick progressions in legalization, today’s cannabis industry bears little resemblance to the industry of five years ago. As the cannabis space gains mainstream acceptance, it resembles more “traditional” industries closely. In turn, how we consume cannabis has changed dramatically within this novel legal framework.

A brief visit to a cannabis dispensary quickly illuminates just how much the industry has changed in the past few years.

Within the dynamic of modern cannabis, perhaps no vertical has seen the same advancements as cannabis extracts. It’s precisely the growth of the concentrate category that has given rise to the many branded products that define the legal market.

To give a clear picture of how advancements in extraction have stimulated the concentrate category’s growth, we put together this brief exploration.

Standards & Technology

extraction equipmentBefore legalization, the production of cannabis extracts was a shady affair done in clandestine and often dangerous ways. Especially concerning BHO (Butane Hash Oil), home-based laboratories have long since been notorious fire hazards. Even more, with a total lack of regulation, black-market extracts are infamous for containing harmful impurities.

In the few short years that cannabis has been legal in Nevada, Washington and other states, extract producers have adopted standards and technology from more professional arenas. By borrowing from the food and pharmaceutical industries, concentrate companies have achieved excellence undreamed of a decade ago.

Good Manufacturing Practices

One of the essential elements in the extracts vertical advancements is the adoption of good manufacturing practices. According to the World Health Organization website, “Good Manufacturing Practice (GMP) is that part of quality assurance which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use.”

When adult-use cannabis was legalized in markets such as Colorado, cannabis companies were able to come out of the shadows and discuss GMPs with legit businesses. In doing so, they implemented professional controls on extract manufacturing in accordance with “quality standards” of state regulatory agencies.

Supercritical CO2 Extraction

As cannabis businesses adopted GMP from other industries, extract producers also embraced more sophisticated technology. Of these, supercritical CO2 has pushed the cannabis concentrates vertical into the future.

IVXX processingAccording to the equipment manufacturer Apeks Supercritical, “CO2 is considered to be a safer method of extraction because the solvent is non-volatile. The extract is purer because no trace of the solvent is left behind. It is also versatile and helps protect sensitive terpenes, by allowing cold separation.” By deriving methods from food production, supercritical equipment manufacturers have given cannabis companies a viable option for the commercial production of extracts.

Supercritical technology has helped push the concentrates vertical forward by providing a clean and efficient way to produce cannabis extracts. Nonetheless, supercritical CO2 equipment is highly sophisticated and carries a hefty price tag. Producers can expect to pay well over $100,000 for commercial supercritical CO2 extraction setup.

Products

Just as standards and technology have evolved in the cannabis extracts vertical, we have also seen products rapidly mature. Notably, the legal environment has allowed manufacturers to exchange ideas and methods for the first time. In turn, this dialogue has led to the development of new products, like isolates and live resin.

Isolates

Just as the name implies, isolates are concentrates made from a singular, pure cannabinoid. In today’s market, CBD isolates have grown increasingly popular because people can consume pure CBD without ingesting other cannabinoids or plant materials, including the legal 0.3% THC found in hemp.

Isolates are made by further purifying cannabis extracts in the process of purification, filtration and crystallization. As seen with other concentrates, isolates are used as the base for many cannabis products, such as gummies.

There is also growing interest in CBG isolate, which is another non-psychoactive cannabinoid when consumed orally.

Live Resin

The cannabis concentrate live resin has taken the industry by storm over the past few years. Live resin is a form of extract that is originally sourced from freshly harvested and frozen cannabis plants. The primary selling point behind this extract is the fact that fresh flowers produce much more vibrant aromas and flavors than dried cannabis. Interestingly, this pungency is tied to the preservation of terpenes in live resin.

Just a few of the dozens of various products types on the market today.

To make live resin, producers “flash freeze” fresh cannabis plants immediately after harvest. Valuable cannabinoids and terpenes are then extracted from the fresh, frozen plant material using hydrocarbon solvents. This whole process is done at extremely cold temperatures, ensuring no thermal degradation to the precious and volatile terpenes.

In lieu of these intricate steps to preserve the flower and extracts, live resin has continuously gained popularity. Namely because vaping with live resin is the best way to sample fresh cannabis terpene profiles in its most authentic fashion

It is amazing to see how much cannabis extracts have grown and progressed with legalization. Due to such amazing advancements in standards, technology, and products, the concentrates category has exploded on the dispensary scene. In today’s market, flowers have been largely sidelined in favor of concentrate-based products like gummies. These products now adorn dispensary shelves in beautiful packaging replete with purity and testing specifications.

It’s an often-overlooked fact that the purity standards of the legal extracts have made reliable cannabis brands possible in the first place. You cannot develop a cannabis brand without consistent products that customers can rely on; all things considered, it can be said that advancements in extraction have not only stimulated the concentrate category but the entire industry as we know it today.

Filed Under: Cannabis News

ACS Laboratory Receives 42 Total Emerald Test Badges, Solidifying its Position as the Industry Leader in Third-Party Cannabis and Hemp Testing

January 12, 2021 by CBD OIL

BOCA RATON, FL ― (Jan. 6, 2021) ―  ACS Laboratory, the largest hemp and cannabis testing facility in the Eastern U.S., received 21 Emerald Test Badges in Fall 2020 for precise and reliable results. This designation marks the second year in a row ACS Laboratory has received 21 badges, totaling 42 Emerald Test Badges in the past two years, and ranking ACS Laboratory at the top of the nation based on Emerald Scientific’s Inter-Laboratory Comparison proficiency test.

“In 2019, ACS Laboratory received 21 Emerald Test Badges and 21 again in 2020, solidifying our position as the top laboratory in the country. The results are a credit to our team’s dedication to accuracy, transparency, and consistency, whether we’re testing oils, flower, edibles, beverages, or topicals,” said Roger Brown, president and founder of ACS Laboratory.

The Emerald Test, developed by Emerald Scientific, compares the efficacy of labs like ACS Laboratory to bring a higher level of standardization across the industry. This fall, ACS Laboratory received awards for potency testing in hemp oils, gummies, and beverages. Additionally, ACS Laboratory passed several tests for accurately detecting contaminants such as residual solvents, heavy metals, molds, and pesticides in hemp and cannabis products.

ACS Laboratory is on a mission to support cannabis companies in their pursuit to deliver clean, safe, and innovative products that promote positive progress in the industry. Always ahead of the curve, ACS Laboratory is continually enhancing its testing methodologies and developing new tests for harmful toxins and therapeutic terpenes, and minor cannabinoids.

ACS Laboratory currently analyzes 20 major and minor cannabinoids, including EXO THC, Delta8 THCV, and Delta10 THC–an unprecedented quantity for U.S. laboratories. Due to its expansive capabilities and rigorous protocols, ACS has teamed up with medical cannabis companies and research universities nationwide to conduct human trials and pharmacokinetic studies.

In spring 2020, ACS Laboratory acquired Botanica Testing, Inc., a certified hemp and CBD testing laboratory, which added 500 new hemp and CBD clients to its rapidly growing portfolio. Thanks to its success, ACS Laboratory has undergone a 20,000 sq. ft. expansion and increased its reach to 47 states and four countries worldwide.

About ACS Laboratory

ACS Laboratory is The Most Trusted Cannabis and Hemp Laboratory in the USA™, earning more Emerald Test Badges for accuracy in testing than any other laboratory in the southeast. ACS Laboratory is ISO 17025 accredited, DEA licensed and CLIA licensed with the largest state-of-the-art facility in the region. Compliant with the USDA’s rules for hemp testing, ACS is also approved by the Florida Department of Agriculture as a “Designated Compliance Laboratory,” and deemed a “Certified Marijuana Testing Laboratory” by the Florida Department of Health. Beyond compliance, ACS is committed to innovation, which is why it tests for more cannabinoids than any lab in the region and continuously develops new protocols to analyze lesser-known toxins. Its facility utilizes industry-leading ultra-high-performance liquid chromatography-tandem mass spectrometry technology and proprietary protocols to ensure accurate detection.

Watch this video about ACS Laboratory, and read the blog for up-to-date information on cannabis science and lab testing for both the hemp and cannabis industries. For more information, visit acslabcannabis.com, or call (813) 670-9157.

Filed Under: CBD Health

QIMA/WQS to Audit Cannabis Companies as CSQ Certification Body

January 12, 2021 by CBD OIL

Back in July of 2020, ASI Global Standards announced the launch of their newest audit standard: The Cannabis Safety & Quality Scheme (CSQ). The scheme is built around ISO requirements and the Global Food Safety Initiative (GFSI) requirements.

In a press release published in December of 2020, CSQ announced they have added a new licensed certification body to the program: QIMA/WQS, which is a provider of independent third-party certification, inspection, and training services for the food industry.

The CSQ program is marketed as the world’s first cannabis certification to meet GFSI criteria, which is expected to get benchmarked in 2022.

The CSQ scheme is built on four standards:

  • Growing and Cultivation of Cannabis Plants
  • Manufacturing and Extraction of Cannabis
  • Manufacturing and Infusion of Cannabis into Food & Beverage Products
  • Manufacturing of Cannabis Dietary Supplements

The first CSQ certifications are expected to be awarded this month. Being a licensed certification body for the CSQ program means QIMA/WQS will conduct document evaluations as well as on-site inspections to ensure companies are meeting the CSQ standards prior to certification.

“At QIMA WQS, we see an enormous potential to support and provide quality certification to the entire cannabis supply chain. Joining CSQ and its innovative approach is an exciting step into the diversification of our services and growth,” says Mario Berard, CEO of QIMA/WQS.

Filed Under: Cannabis News

Canadians Want CBD To Be Exempt From Cannabis Rules, Consultation Suggests

January 12, 2021 by CBD OIL

The results of Canada’s public consultation on health products containing cannabis have been released in report form, showing strong support for allowing the sale of cannabidiol (CBD) outside the current cannabis restrictions.

The consultation on whether to modify regulations to allow the sale of CBD as a non-prescription health and wellness products was conducted earlier in the year by Health Canada, the country’s health authority. What was in question was essentially whether the sale of CBD products should be permitted outside the country’s legal cannabis regime, under which all derived products currently fall.

Health Canada said it had received responses from consumers (62% of responses), industry representatives (23%), and other interested parties (15%). A further 73 written statements that did not specifically respond to the questions posed were received from other groups.

The vast majority (93%) of consumers were interested in being able to purchase cannabis products intended to treat minor ailments–such as CBD creams for muscle pain–with only 2% opposed and the remainder interested, depending on having further information available.

“Consumers indicated a strong interest in products containing CBD throughout the online questionnaire. Moreover, 105 respondents provided additional comments in favor of access to CBD for therapeutic purposes without practitioner oversight,” Health Canada said. “Participants suggested CBD should not be regulated the same way as other substances or products, such as tetrahydrocannabinol (THC), alcohol, or other pharmaceutical drugs, which they view to be more harmful.”

Interest in products for a wide range of ailments was reported, with the most common being some form of pain or inflammation, followed by mental conditions such as anxiety, depression, or stress.

Similarly, there was interest in most product formats, with oral items like extracts, tinctures, oils, capsules, and sublinguals leading the way, being highlighted by 61% of respondents. Topicals such as creams or lotions came in second, with 41% respondent interest.

Health Canada also noted interest in edibles/beverages and smoking/vaping formats, though these lagged far behind.

Many consumer respondents added that they would not want a completely unregulated market but would favor some level of oversight and regulatory control to remain.

“Respondents encouraged Health Canada’s approval of these types of products to ensure safety and quality, while allowing consumer choice and increased access to a wider array of products without practitioner oversight,” the report stated.

There was concern over retail place of sale for CBD and other non-pharmaceutical cannabis-derived health products if they were to be permitted. A number of respondents said it would make sense not to restrict sales to provincially- or territorially-authorized retailers or federally licensed cannabis sellers.

“Allowing CHPs [cannabis health products] to be sold at pharmacies, health stores, or other retailers would improve availability and deter from the stigma associated with cannabis use,” Health Canada summarised.

CBD products–particularly oral and topical–were also the main objects of interest to industry; 24 industry representatives indicated a desire to combine CBD with other cannabis-derived ingredients such as THC, flavonoids, and terpenes, as well as approved natural health products (NHPs) like vitamins, minerals, essential oils, and herbs.

“With respect to health claims of interest, industry representatives from all groups emphasized their preference for providing CHPs for pain relief, inflammation, sleep disorders, and anxiety,” Health Canada said. “Other areas of interest include skin conditions (e.g., eczema, psoriasis) and digestive issues.”

Evidence standards divided opinion among industry representatives, with a third of those addressing the issue highlighting the need for robust scientific interest and the remaining two thirds claiming such requirements would discourage research and innovation.

“Of these respondents, a few representatives from NHP and veterinary health products companies also mentioned that they would like to be able to use traditional evidence or make general health promotion claims on CHPs,” Health Canada noted.

Unsurprisingly, retailing restrictions were almost universally opposed by industry representatives in favor of the sale of CBD and other cannabis-derived health products outside the current regulatory framework. Limitations to provincially or territorially authorised retailers or federally licensed cannabis sellers would be a massive disincentive.

Many also said they had concerns that employees in licensed recreational facilities would not have the knowledge or training to assist customers. That added to the potential for consumer confusion between recreational cannabis products and cannabis-derived health products sold in such a setting.

There were also concerns that current packaging and labelling proposals would similarly stymie the industry, with respondents expressing a preference for a broader ability to promote and distinguish their products on the market.

“Respondents proposed that the requirements should be similar to any other NHP or over-the-counter drug to compete with the illicit market,” Health Canada said.

Industry representatives said the process offered an opportunity for Canadian regulators to differentiate between THC and CBD.

“About half of the written submissions from the cannabis and NHP industries proposed creating two distinct pathways for CHPs that appropriately reflect their risk profiles,” the report said.

“Specifically, they suggested establishing two different pathways for CHPs with THC and CHPs with CBD. Furthermore, each potential pathway would have its own requirements for packaging and labelling, retail environment, youth access, and evidence standards.”

Health Canada will now continue putting together a scientific advisory committee to gather further information on the safety, efficacy and quality standards for health products containing cannabis that would be safe for use without practitioner oversight.

Original article: https://www.cbd-intel.com/canadian-public-and-industry-back-plan-to-free-cbd-from-cannabis-regulation/

Image Credit: Chickenonline

Image Source: https://pixabay.com/illustrations/canada-north-america-national-flag-1157521/

CBD-Intel provides impartial, independent, and premium market and regulatory analysis, legal tracking, and quantitative data for the CBD sector.

We provide our clients with the tools to navigate this fast-moving sector, tailor their business strategy, optimize resources, and make informed decisions. In addition, we offer customized research and consultancy support.

Filed Under: CBD Health

Hemp’s Future in Latin America

January 12, 2021 by CBD OIL

When reporting on the hemp industry, it’s not uncommon for Latin American markets (LATAM) to be left out of the conversation entirely. This is largely the case because it is believed that LATAM hemp is in its early infancy. But, in reality, societal views towards hemp and its potential as a cash crop have begun to shift in pockets from Uruguay to Mexico. This progress has not been without obstacles, however.

According to an LATAM market report by the Brightfield Group, hemp-derived cannabidiol (CBD) sales could reach as high as $448 million by 2023. Although medical cannabis is deemed legal in multiple countries across LATAM, projected sales lag far behind CBD at $109 million by 2023. This massive divide can be attributed to negative views toward cannabis, which has long been tied to violent drug cartels.

Although it may be disappointing that cannabis legalization is a way off, hemp is not subject to the same stigmatization because it contains much lower THC levels, leading to a different classification altogether in the mind of society and the policies of government. In Mexico, for example, the legality of CBD products with <1% THC has increased access and boosted the market considerably.

And, in Uruguay, which fully legalized cannabis in 2013, the hemp market has blossomed, priming Uruguay to become one of the largest exporters of hemp-based products within LATAM in 2020–especially with increased investor interest in launching hemp-growing operations across the country. Up-and-coming hemp markets can also be found in Mexico, Peru, Chile, and Paraguay. Another stand out example is Colombia, where CBD products can be legally purchased through government-licensed retailers. Suffice it to say, interest in hemp products, such as CBD, is increasing across multiple LATAM nations.

Long-term projections indicate that, as in the US, skincare and beauty products are likely to take the lead in sales in LATAM. And, due to lower cost of these products, it is likely that interest among consumers will continue to grow.

Although it’s too early to make concrete predictions, hemp’s future in LATAM appears to be a bright one. As more LATAM countries continue to re-evaluate their legal stance on cannabis, the possibility of a robust hemp market coming to fruition becomes even more likely. In the interim, one can only hope that LATAM countries with fledgling markets will be able to find willing foreign investors to bolster a newly found industry.

Image Credit: Robert6129

Image Source: https://pixabay.com/photos/hemp-seedling-hemp-leaf-hemp-plant-3662166/

Filed Under: CBD Health

CULTA Announces Move to New Bethesda Office to Support Continuing Growth

January 12, 2021 by CBD OIL

Common Citizen, a vertically integrated business in Michigan’s medical and adult-use cannabis markets, brought on Allison Hornev as the company’s chief marketing officer. Hornev arrives from Bell’s Brewery Inc., another stalwart of the Michigan landscape. 

The move is a good example of that bridge between the breweries and cannabis cultivation facilities. Each market tends to connoisseurs and new customers alike, making the story behind a brand incredibly important. Before Bell’s, Hornev worked as Kellogg’s.

“Through Allison’s marketing expertise, she will help our continued efforts to identify and serve the unique needs of every patient and adult-use customer at all Common Citizen retail and wholesale locations as we continue expanding our footprint here in Michigan and beyond,” CEO Mike Elias said.

We spoke with Hornev about her plans for Common Citizen and the cannabis business in general.

Eric Sandy: What brought about your interest in the cannabis space and in Common Citizen?

allison hornev

Courtesy of Common Citizen

Hornev

Allison Hornev: It’s funny: I wasn’t interested in the cannabis industry. I was very happy working for Bell’s. It’s an amazing company with an amazing culture. But then I met one of the founders [of Common Citizen], and we just started having conversations and started talking about the opportunity. And at that point, I got to know the brand more and know the founders and understand what they’re wanting to do with cannabis and in this very busy market that we’re in. That’s really what turned me on to it: that great opportunity that Common Citizen has to not just sell cannabis but make a difference. You see that coming through our commitment to safety and safe products and the idea of cannabis for humanity: How do we debunk the stigma so people feel comfortable using it to help them, or using it however they choose. That, to me, is really what made the difference. It just stood for more in my eyes.

ES: Common Citizen has some interesting terminology that customers can use, whether it’s “chapters,” “citizen advisers” and, of course, all the in-store categories for different cannabis products. Could you talk a bit about why that is important?  

AH: From a business standpoint, it allows you to stand apart in a very crowded market. But, honestly, it’s going to get more crowded before it consolidates, right? So, it allows you to stand apart, but it also allows you to talk to the people, to the consumers and to our patients from a different voice. And to me, that voice is a more caring voice. That voice is a more passionate voice and a more approachable voice. And I think that is really powerful.

ES: We featured Common Citizen in a piece about the design of their Flint store. Could you talk a bit about how things like interior design can help shape the story of a company?

AH: I think oftentimes it’s overlooked, right? “We’re just going to put up a store and sell some cannabis.” Again, as a lot of things with Common Citizen, it’s more than that. It’s creating an environment that is welcoming, that is very concierge-based and it’s helping the patient or the consumer through that journey and spending time with them. You look at that Flint store and it’s got that area off to the side with the couches, where we can sit down and have a conversation about what it is you’re looking for or what it is you need or what your desires and hopes and dreams are. That’s where we can really get to know you and provide you something that will be beneficial and provide you an experience that you then enjoy—or one that helps you. Then you do feel more comfortable every time you come back. And I think the interior design just builds and allows for that to happen

ES: And certainly a lot of those same ideas are at play over at Bell’s. Is there a helpful sense of marketing crossover that might be a play between craft beer and cannabis?

AH: Yeah, it’s fascinating. On the surface right there, you’ve got the 21-and-plus audience. If you look at craft beer and beer in general and adult beverages—and it is incredibly saturated, there’s a lot of players—and you look at how Larry [Bell] has built this business to stand apart and stand for things for the 35 years he’s been in business. He has built what Bell’s stands for now and its quality and its consistency and its great branding, and it’s continuing to provide new and different things. And then when you come to the cannabis industry, again, it’s so oversaturated and there’s so much out there and it can be, to a consumer, to somebody that’s new into it, overwhelming just like beer. So, how do I take what I learned through my years at Bell’s—and even before that at Kellogg’s—and apply that here to help those consumers in that space and stand for those key things that are so important right now?

For us at Common Citizen, it’s safety. And that leads to quality and that leads to approachable brands that aren’t intimidating—brands for that common citizen, you know? That’s what we’re built off of. Just in talking to you in this conversation, it gives me goosebumps. It makes me smile. But this is something we’re out to do. We’re out to help people and help them feel comfortable with that decision.

ES: I did want to touch on Michigan in particular. What does it mean to have Michigan as a backdrop for Common Citizen?

AH: It provides just tons of opportunities. When you look at Michigan, you see, just in a short time, where we’ve come with cannabis. From medical and then phasing into rec, the future is so incredibly bright for Michigan in this space. Leaning into our roots and being true to where we’ve come from, that’s important. The founders are all boys that grew up in Detroit. There’s such heart there. And it’s such a great story for us as a brand.

I think Michigan is going to be a state to look at in this industry, and it’s going to be sought after. People are going to learn a lot, and other states are going to learn a lot from what we’re able to do here at Michigan.

And I think that’s why it’s so important that we are leading by example and that we are building a GMP facility, even though it’s not necessary to do so in the regulations. We feel that that’s the right thing to do to ensure that safety. If we can lead by example here in Michigan and get some friends to come along and do that with us, I think that will help other states learn from us. That will help other brands learn from us. You look at beer 100 years ago, and they were just coming back online from Prohibition and there was a lot of work to do. I don’t think we’re 100 years back, but there’s a lot ahead of us.

ES: With the new year upon us, what are some of your short-term goals at Common Citizen?

AH: Honestly, I’m still getting my feet wet. Short-term, I’ve got to just be a sponge. It is absolutely my goal to talk to everybody here, from the greenhouse to the executive team, to the investors—talk to our retail locations and our budtenders and talk to our wholesalers and spend time with them understanding the market in general and what the needs are. I believe that there are needs currently unmet, so how can we do that? How can we stand apart? It is absolutely my goal to be the leader in Michigan, and to do that in a couple of different ways. Not just through volume and sales, but through advocacy and through safety and through being that shining star in this very crazy industry right now. That is both long-term and short-term, and I think the team here has already set us up for great success there. Now, it is my job and responsibility to continue to carry us there.

 

Filed Under: Cannabis News

What's Happening in the 'Canopy Growth v. GW Pharmaceuticals' Lawsuit?

January 12, 2021 by CBD OIL

<![CDATA[

Canopy Growth Corp., one of the largest cannabis producers in the world, filed a federal lawsuit in late 2020 against GW Pharmaceuticals, the UK-based cannabis business behind the FDA-approved Epidiolex. At issue is an extraction method that Canopy asserts is newly protected by patent.

Read the full complaint below.

Canopy Growth alleges that GW Pharmaceuticals produces Epidiolex via the protected CO2 extraction method. Since its 2018 approval from the FDA, GW then distributes Epidiolex across the U.S. and elsewhere at $1,235 per 100mL bottle. “GW reported approximately $366 million in net product sales of Epidiolex in the United States in the first nine months of 2020,” according to the lawsuit.

Although the patent protection on this extraction method is a new issue for Canopy Growth, an earlier iteration of the patent in question was published in 2000. Its contents were acquired by Canopy Growth Corp. amid an acquisition of Germany’s C3 Cannabinoid Compound Company (founded by Bionorica SE), a company with which GW allegedly considered partnering in 2016 for its cannabinoid processing work.

Canopy Growth specifically points to two claims in its patent, asserting that GW Pharmaceuticals performs the described actions in its manufacture of Epidiolex.

For example, in Claim 1 of the patent, Canopy Growth writes:

A process for producing an extract containing Tetrahydrocannabinol (THC) and/or cannabidiol (CBD), and optionally the carboxylic acid thereof, from a cannabis plant material or a primary extract thereof, said processing comprising:

(1)   Subjecting the cannabis plant material or primary extract thereof to CO2 in liquefied form under subcritical pressure and temperature conditions to extract cannabinoid components; and

(2)   reducing the pressure and/or temperature to separate tetrahydrocannabinol and/or cannabidiol, and optionally the carboxylic acids thereof, from the CO2.

This lawsuit is the first action Canopy has taken to argue its patent. Marijuana Moment first reported on the contents of this lawsuit in December. 

The case echoes the UCANN v. Pure Hemp lawsuit that we covered in 2019. UCANN went after Pure Hemp for cannabis tincture formulation that fell under a patent for “liquid cannabinoid formulations wherein at least 95% of the total cannabinoids” is THCa THC, a combination of THCa and CBDa, and a combination of THC and CBD. In other words, the patent covered a broad swath of the cannabis concentrate market segment. 

In April 2020, UCANN filed for Chapter 11 bankruptcy, and the federal lawsuit was administratively closed by the court.

 

Canopy Growth Corp. vs. GW Pharmaceuticals by sandydocs on Scribd

 

]]>

Filed Under: Cannabis News

Former Bell’s Brewery Marketing Manager Takes Leadership Role at Common Citizen

January 12, 2021 by CBD OIL

Common Citizen, a vertically integrated business in Michigan’s medical and adult-use cannabis markets, brought on Allison Hornev as the company’s chief marketing officer. Hornev arrives from Bell’s Brewery Inc., another stalwart of the Michigan landscape. 

The move is a good example of that bridge between the breweries and cannabis cultivation facilities. Each market tends to connoisseurs and new customers alike, making the story behind a brand incredibly important. Before Bell’s, Hornev worked as Kellogg’s.

“Through Allison’s marketing expertise, she will help our continued efforts to identify and serve the unique needs of every patient and adult-use customer at all Common Citizen retail and wholesale locations as we continue expanding our footprint here in Michigan and beyond,” CEO Mike Elias said.

We spoke with Hornev about her plans for Common Citizen and the cannabis business in general.

Eric Sandy: What brought about your interest in the cannabis space and in Common Citizen?

allison hornev

Courtesy of Common Citizen

Hornev

Allison Hornev: It’s funny: I wasn’t interested in the cannabis industry. I was very happy working for Bell’s. It’s an amazing company with an amazing culture. But then I met one of the founders [of Common Citizen], and we just started having conversations and started talking about the opportunity. And at that point, I got to know the brand more and know the founders and understand what they’re wanting to do with cannabis and in this very busy market that we’re in. That’s really what turned me on to it: that great opportunity that Common Citizen has to not just sell cannabis but make a difference. You see that coming through our commitment to safety and safe products and the idea of cannabis for humanity: How do we debunk the stigma so people feel comfortable using it to help them, or using it however they choose. That, to me, is really what made the difference. It just stood for more in my eyes.

ES: Common Citizen has some interesting terminology that customers can use, whether it’s “chapters,” “citizen advisers” and, of course, all the in-store categories for different cannabis products. Could you talk a bit about why that is important?  

AH: From a business standpoint, it allows you to stand apart in a very crowded market. But, honestly, it’s going to get more crowded before it consolidates, right? So, it allows you to stand apart, but it also allows you to talk to the people, to the consumers and to our patients from a different voice. And to me, that voice is a more caring voice. That voice is a more passionate voice and a more approachable voice. And I think that is really powerful.

ES: We featured Common Citizen in a piece about the design of their Flint store. Could you talk a bit about how things like interior design can help shape the story of a company?

AH: I think oftentimes it’s overlooked, right? “We’re just going to put up a store and sell some cannabis.” Again, as a lot of things with Common Citizen, it’s more than that. It’s creating an environment that is welcoming, that is very concierge-based and it’s helping the patient or the consumer through that journey and spending time with them. You look at that Flint store and it’s got that area off to the side with the couches, where we can sit down and have a conversation about what it is you’re looking for or what it is you need or what your desires and hopes and dreams are. That’s where we can really get to know you and provide you something that will be beneficial and provide you an experience that you then enjoy—or one that helps you. Then you do feel more comfortable every time you come back. And I think the interior design just builds and allows for that to happen

ES: And certainly a lot of those same ideas are at play over at Bell’s. Is there a helpful sense of marketing crossover that might be a play between craft beer and cannabis?

AH: Yeah, it’s fascinating. On the surface right there, you’ve got the 21-and-plus audience. If you look at craft beer and beer in general and adult beverages—and it is incredibly saturated, there’s a lot of players—and you look at how Larry [Bell] has built this business to stand apart and stand for things for the 35 years he’s been in business. He has built what Bell’s stands for now and its quality and its consistency and its great branding, and it’s continuing to provide new and different things. And then when you come to the cannabis industry, again, it’s so oversaturated and there’s so much out there and it can be, to a consumer, to somebody that’s new into it, overwhelming just like beer. So, how do I take what I learned through my years at Bell’s—and even before that at Kellogg’s—and apply that here to help those consumers in that space and stand for those key things that are so important right now?

For us at Common Citizen, it’s safety. And that leads to quality and that leads to approachable brands that aren’t intimidating—brands for that common citizen, you know? That’s what we’re built off of. Just in talking to you in this conversation, it gives me goosebumps. It makes me smile. But this is something we’re out to do. We’re out to help people and help them feel comfortable with that decision.

ES: I did want to touch on Michigan in particular. What does it mean to have Michigan as a backdrop for Common Citizen?

AH: It provides just tons of opportunities. When you look at Michigan, you see, just in a short time, where we’ve come with cannabis. From medical and then phasing into rec, the future is so incredibly bright for Michigan in this space. Leaning into our roots and being true to where we’ve come from, that’s important. The founders are all boys that grew up in Detroit. There’s such heart there. And it’s such a great story for us as a brand.

I think Michigan is going to be a state to look at in this industry, and it’s going to be sought after. People are going to learn a lot, and other states are going to learn a lot from what we’re able to do here at Michigan.

And I think that’s why it’s so important that we are leading by example and that we are building a GMP facility, even though it’s not necessary to do so in the regulations. We feel that that’s the right thing to do to ensure that safety. If we can lead by example here in Michigan and get some friends to come along and do that with us, I think that will help other states learn from us. That will help other brands learn from us. You look at beer 100 years ago, and they were just coming back online from Prohibition and there was a lot of work to do. I don’t think we’re 100 years back, but there’s a lot ahead of us.

ES: With the new year upon us, what are some of your short-term goals at Common Citizen?

AH: Honestly, I’m still getting my feet wet. Short-term, I’ve got to just be a sponge. It is absolutely my goal to talk to everybody here, from the greenhouse to the executive team, to the investors—talk to our retail locations and our budtenders and talk to our wholesalers and spend time with them understanding the market in general and what the needs are. I believe that there are needs currently unmet, so how can we do that? How can we stand apart? It is absolutely my goal to be the leader in Michigan, and to do that in a couple of different ways. Not just through volume and sales, but through advocacy and through safety and through being that shining star in this very crazy industry right now. That is both long-term and short-term, and I think the team here has already set us up for great success there. Now, it is my job and responsibility to continue to carry us there.

 

Filed Under: Cannabis News

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 89
  • Go to page 90
  • Go to page 91
  • Go to page 92
  • Go to page 93
  • Interim pages omitted …
  • Go to page 118
  • Go to Next Page »

Footer

  • Home
  • Privacy Policy
  • Terms of Service